ARA-290: Benefits, Dosage & FDA Status
ARA-290 (Cibinetide)
An 11-amino-acid peptide derived from the helix-B region of erythropoietin. Activates the tissue-protective receptor without erythropoietic side effects. Investigated for neuropathy and inflammation.
FDA Status
Not FDA-approved — Phase 2/3 trials for sarcoidosis-associated small fiber neuropathy
Typical Dose
Trial range: 1–4 mg subcutaneous daily
Evidence Grade
BLimited clinical + robust preclinical evidence
Half-Life
Minutes (effects last hours)
Routes of Administration
subcutaneous
First Synthesized
2010
Clinics Indexed
9 providers have offered ARA-290 in our tracked directory.
Mechanism of Action
Selective agonist at the EPOR/βCR heteromer (tissue-protective receptor) without binding the erythropoietic homodimer.
Key Reported Benefits
- ✓Small-fiber neuropathy improvement
- ✓Anti-inflammatory
- ✓No erythrocytosis
Benefits listed reflect commonly reported effects from clinical trials and practitioner use. Individual response varies. Evidence-grade B indicates limited clinical + robust preclinical evidence.
Reported Side Effects
- •Generally well-tolerated
- •Injection-site reactions
Contraindications
- ⚠Pregnancy
Regulatory & Safety Context
FDA status: Not FDA-approved — Phase 2/3 trials for sarcoidosis-associated small fiber neuropathy
This page is for educational purposes only and does not constitute medical advice. Peptide use outside of an FDA-approved indication should be discussed with a licensed medical professional. Source quality, cold-chain storage, and injection hygiene all materially affect safety outcomes.
See state-by-state legality: US peptide legality by state →
References
Selected primary literature on ARA-290. Full PubMed records linked. Additional citations are available on request.
Last reviewed: 2026-04-30
Related Peptides
VIP
BA 28-amino-acid neuropeptide with broad immunomodulatory effects. Used clinically (intranasal) by some practitioners for chronic inflammatory response syndrome (CIRS).
TB-500
BA synthetic fragment of thymosin beta-4 that promotes cell migration, blood vessel formation, and tissue repair. Often stacked with BPC-157 as the 'Wolverine Stack.'
Semax
BA synthetic ACTH fragment that increases BDNF levels and enhances focus, memory, and mental clarity. Delivered intranasally for rapid cognitive effects.
Thymosin Alpha-1
AA 28-amino-acid thymic peptide that matures and modulates T-cells. Used internationally as an adjunct in hepatitis, sepsis, and immune-compromised cancer care.
DSIP
CA nonapeptide originally isolated from rabbit blood after EEG-defined slow-wave sleep induction. Inconsistent human evidence for sleep but explored for stress and analgesia.
KPV
C+The C-terminal tripeptide of α-MSH with documented anti-inflammatory activity in IBD and dermatitis preclinical models. Frequently delivered orally and topically.